Alimera Stock Story

ALIM

Stock

USD 7.00 0.18 2.51%

Macroaxis Story

It looks like FSD Pharma will continue to recover faster as its price went down 3.06% today to Alimera Sciences's 2.57%. As many investors are getting excited about healthcare space, Alimera Sciences and FSD Pharma may be going in opposite directions. We are going to summarize some of the competitive aspects of both Alimera and FSD Pharma.

Published over three months ago

View all stories for Alimera Sciences | View All Stories

Are retail investors acquiring Alimera Sciences (NASDAQ:ALIM) or FSD Pharma?

By analyzing existing forward indicators between Alimera Sciences and FSD Pharma, you can compare the effects of market volatilities on both companies' prices and check if they can diversify away market risk if combined in one of your portfolios. You can also utilize pair trading strategies for matching a long position in FSD Pharma with a short position in Alimera Sciences. Check out our pair correlation module for more information.

Let's begin by analyzing the assets.

The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Alimera Sciences has an asset utilization ratio of 78.73 percent. This denotes that the company is making $0.79 for each dollar of assets. An increasing asset utilization means that Alimera Sciences is more efficient with each dollar of assets it utilizes for everyday operations.

Are retail investors acquiring Alimera Sciences (NASDAQ:ALIM) or FSD Pharma?

How important is Alimera Sciences's Liquidity

Alimera Sciences financial leverage refers to using borrowed capital as a funding source to finance Alimera Sciences ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Alimera Sciences financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Alimera Sciences's total debt and its cash.

How does Alimera utilize its cash?

To perform a cash flow analysis of Alimera Sciences, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Alimera Sciences is receiving and how much cash it distributes out in a given period. The Alimera Sciences cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.

Alimera Sciences Net Cash Flow from Operations is relatively stable at the moment as compared to the past year. The company's current value of Net Cash Flow from Operations is estimated at (3.48 Million)

Breaking down the case for Alimera Sciences

Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include product or services discounts, promotions, as well as early payments on invoices or services rendered in advance.

Revenue Breakdown

Now, let's check Alimera Sciences revenue. Based on the latest financial disclosure, Alimera Sciences reported 59.03 M of revenue. This is 99.23% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The revenue for all United States stocks is 99.37% higher than that of Alimera Sciences. As for FSD Pharma we see revenue of 11.91 M, which is much higher than that of the Drug Manufacturers—Specialty & Generic

	Alimera	59.03 Million
	Sector	0.0
	FSD Pharma	11.91 Million

59 M

Alimera

Sector

11.9 M

FSD Pharma

Analysis of Alimera Sciences

New coefficient of variation is at 918.33.

As of the 9th of May, Alimera Sciences shows the Mean Deviation of 2.69, downside deviation of 3.6, and Risk Adjusted Performance of 0.1456. Alimera Sciences technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to collect and analyze data for nineteen technical drivers for Alimera Sciences, which can be compared to its rivals. Please confirm Alimera Sciences variance, as well as the relationship between the maximum drawdown and semi variance to decide if Alimera Sciences is priced correctly, providing market reflects its regular price of 5.31 per share. Given that Alimera Sciences has jensen alpha of 0.3724, we suggest you to validate Alimera Sciences's prevailing market performance to make sure the company can sustain itself at a future point.

Our Takeaway on Alimera Sciences Investment

While some other companies under the drug manufacturers—specialty & generic industry are still a bit expensive, Alimera Sciences may offer a potential longer-term growth to stakeholders. While some stakeholders may not share our view we believe that the current risk-reward utility is not appealing enough to do any trading. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Alimera Sciences.

Editorial Staff

Gabriel Shpitalnik is a Member of Macroaxis Editorial Board. Gabriel is a young entrepreneur and writes predominantly on the business, technology, and finance sector. He likes to analyze different equity instruments across a wide range of industries focusing primarily on consumer products and evolving technologies. View Profile

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Gabriel Shpitalnik do not own shares of Alimera Sciences. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2022 Macroaxis LLC